News
ProBioGen and Merus Sign Deal on GlymaxX® ADCC Enhancement Technology
March 04, 2014
- GlymaxX® Manufacturing Technology Improves Bispecific Antibody Activity for Solid Tumor Treatment -
Berlin, Germany, and Utrecht, The Netherlands - March 4, 2014 - ProBioGen AG and Merus B.V. today anno...
Read more
ISA Pharmaceuticals Strengthens Patent Protection for its Lead Product ISA101
February 24, 2014
- Granted EU patent provides market exclusivity until 2028 -
Leiden, The Netherlands, February 24, 2014 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed the...
Read more
Synthon Biopharmaceuticals ramping up for initiation of Phase I study with its frontrunner ADC SYD985
January 14, 2014
Nijmegen, the Netherlands, January 14, 2014 - In its quest to develop medications to treat serious diseases, Synthon Biopharmac...
Read more
InteRNA Technologies, UCB and University of Bonn to collaborate on the role of microRNAs in neurodegenerative disease
January 10, 2014
Nijmegen/Utrecht (the Netherlands), January 10 2014 - InteRNA Technologies B.V., the Dutch biopharma company engaged in the development of microRNA (miRNA)-based therapeutics, and the Neuroallianz Consortium...
Read more
MiRacle Consortium led by InteRNA Technologies and VU University Medical Center Along with Quiet Therapeutics Receives a € 1.2 million FP7 Grant from the European Union
November 04, 2013
- Therapeutic development of cancer cell-specific targeting of novel tumor-selective lethal miRNAs for the treatment of head and neck cancer - acronym: MiRacle -
Nijmegen/Utrecht and Amsterdam (the Netherla...
Read more
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial With ISA101 in Women with Cervical Cancer
October 29, 2013
- Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested together with chemotherapy in women with HPV16-positive advanced or recurrent cervical cancer -
Leiden, The Netherlands, October 29...
Read more
Merus Granted European Patent on MeMo®, a Transgenic Mouse for Generating the Building Blocks of Therapeutic Human Bispecific Antibodies
October 23, 2013
- Invention provides unique technology base for therapeutic human bispecific antibodies
- Full-length IgG format of bispecific antibodies facilitates standard manufacturing processes
Utrecht, The Netherl...
Read more
ISA Pharmaceuticals Establishes Advisory Board
October 15, 2013
- Renowned Specialists to Support Development of ISA's Advancing Pipeline -
Leiden, The Netherlands, October 15, 2013 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationall...
Read more
Merus Secures €31 Million in Series B Round Extension
October 03, 2013
Investment brings Series B to a total of €47.6 million
Johnson and Johnson Development Cooperation joins as new investor; receives board seat
Utrecht, The Netherlands, October 3, 2013 - Merus B.V., a bioph...
Read more
ISA Pharmaceuticals Presents Novel Data at the European Cancer Congress 2013: Strong Synergies Between Cancer Vaccine ISA101 and Chemotherapy
September 30, 2013
Chemotherapy improves immune response to therapeutic vaccine against Human Papilloma Virus type 16 (HPV16)
Leiden, The Netherlands, September 30, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmac...
Read more
ISA Pharmaceuticals Initiates Phase I/II Clinical Trial of ISA101 in Patients with Anal Intraepithelial Neoplasia (AIN)
September 16, 2013
Therapeutic vaccine against Human Papilloma Virus type 16 (HPV16) tested in HIV-positive male patients
Leiden, The Netherlands, September 16, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceuti...
Read more
ORCA Therapeutics strengthens Scientific Advisory Board
September 05, 2013
Amsterdam, The Netherlands - September 3th, 2013 - ORCA Therapeutics BV, a pioneer in the development of innovative virotherapies for treatment of cancer, announced today that it has expanded its Scientific...
Read more
ISA Pharmaceuticals Strengthens Management Team
July 08, 2013
Company hires Jan Fagerberg as Chief Medical Officer and Jens Hennecke as Chief Business Officer
Ronald Loggers becomes Acting Chief Executive Officer and Gerard Platenburg Chief Operating Officer
Leiden, Th...
Read more
Merus Presents Preclinical Data on its Novel Bispecific Antibody MCLA-117 at EHA 2013
June 17, 2013
Clinical Candidate Designed for the Treatment of Acute Myeloid Leukemia (AML)
Utrecht, The Netherlands, June 17, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeu...
Read more
SUPPRESTEM Consortium Led by Merus Receives €6 Million FP7 Grant from the European Union
May 27, 2013
Development of Therapeutic Bispecific Antibodies (Biclonics™) Targeting Treatment-resistant Cancer Stem Cells Using Patient-Derived Organoid Screening Tools
Utrecht, The Netherlands, May 27, 2013 - Merus B....
Read more
Novel AMPLIVANT™ Technology Introduced at AACR Annual Meeting 2013
April 12, 2013
AMPLIVANT™ TLR-ligand adjuvant to improve immunotherapies
Leiden, The Netherlands, April 9, 2013 - ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed ther...
Read more
InteRNA Technologies secures additional equity financing to progress lead program for melanoma treatment
March 26, 2013
Utrecht/Amsterdam, The Netherlands, March 26, 2013 - InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces today the closing...
Read more
Merus Further Expands R&D Capacity
March 07, 2013
Company Contracts R&D Service Provider FairJourney Biologics
Utrecht, The Netherlands, March 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutics, today annou...
Read more
Merus Achieves Milestone with Novartis Option Fund
February 07, 2013
Company Reaches Milestone in Biclonics™ Program Partnered with Novartis
Utrecht, The Netherlands, February 7, 2013 - Merus B.V., a biopharmaceutical company focusing on innovative human antibody therapeutic...
Read more
OcellO and Merus sign agreement for screening bispecific cancer antibodies
January 14, 2013
Leiden and Utrecht, The Netherlands, January 14, 2013 - OcellO B.V. and Merus B.V. have entered into a collaboration under which OcellO will provide screening services to Merus. OcellO will use its 3D cell c...
Read more
